Skip to main content

Mazabraud Yann's Form 4 filing

Rhythm Pharmaceuticals, Inc. (RYTM) · filed Feb 13, 2024

Accession no.
0001104659-24-022539
Filed
Feb 13, 2024
Trade date
Feb 9-13, 2024
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $129.6K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mazabraud YannCIK 0001774702Officer (EVP, Head of International)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 9, 2024Common StockMOption exerciseAcquired+3,438–F1–7,265Direct
Feb 11, 2024Common StockMOption exerciseAcquired+2,031–F1–9,296Direct
Feb 12, 2024Common StockSSaleDisposed−1,594$51.38−$81,899.727,702Direct
Feb 13, 2024Common StockSSaleDisposed−957$49.84−$47,696.886,745Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 9, 2024Common StockMOption exerciseDisposed−3,438$0.00$06,874Direct
Feb 11, 2024Common StockMOption exerciseDisposed−2,031$0.00$02,031Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Referenced by the price of 2 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)